Rigel Pharmaceuticals (RIGL)
Commercializes specialty treatments for a blood disorder, a leukemia, and RET-fusion cancers in the US.
$48.14
After hours−0.66 (−1.36%)
At close$48.81(+3.64%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28 | 36 | 30 | 37 | 55 | 58 | 53 | 102 | 69 | 70 | 59 | 79 |
| Cost of revenue | 1 | 4 | 2 | 3 | 8 | 6 | 4 | 5 | 5 | 6 | 5 | 9 |
| Gross profit | 27 | 32 | 28 | 34 | 47 | 52 | 49 | 97 | 65 | 64 | 54 | 70 |
| 31 | 30 | 34 | 34 | 33 | 35 | 36 | 36 | 36 | 41 | 42 | 47 | |
| Research & development | 6 | 3 | 6 | 6 | 6 | 6 | 8 | 7 | 7 | 11 | 12 | 14 |
| 25 | 27 | 28 | 28 | 27 | 30 | 28 | 29 | 29 | 30 | 31 | 33 | |
| Selling & marketing | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −4 | 2 | −7 | 0 | 14 | 17 | 13 | 61 | 28 | 23 | 12 | 24 |
| −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | 0 | 0 | 0 | |
| Interest income | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest expense | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Other non-operating income | −1 | −1 | −1 | −1 | 0 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| Income before tax | −6 | 1 | −8 | −1 | 12 | 15 | 12 | 60 | 28 | 23 | 12 | 24 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | −245 | 3 | 6 |
| Net income from continuing operations | −6 | 1 | −8 | −1 | 12 | 14 | 11 | 60 | 28 | 268 | 9 | 17 |
| Net income | −6 | 1 | −8 | −1 | 12 | 14 | 11 | 60 | 28 | 268 | 9 | 17 |
| EPS, basic | −$0.33 | $0.04 | −$0.47 | −$0.06 | $0.71 | $0.81 | $0.64 | $3.33 | $1.55 | $14.72 | $0.47 | $0.93 |
| EPS, diluted | −$0.33 | $0.04 | −$0.47 | −$0.06 | $0.70 | $0.80 | $0.63 | $3.28 | $1.46 | $13.54 | $0.44 | $0.88 |
| Weighted average shares, basic | 17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 |
| Weighted average shares, diluted | 17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 20 | 20 |
| EBITDA | −4 | 3 | −6 | 2 | 15 | 18 | 14 | 62 | 30 | 25 | 14 | 25 |
| Depreciation & amortization | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBIT | −4 | 3 | −6 | 1 | 14 | 17 | 13 | 62 | 30 | 24 | 13 | 24 |